ChengDu ShengNuo BiotecLtd Future Growth
Future criteria checks 5/6
ChengDu ShengNuo BiotecLtd is forecast to grow earnings and revenue by 33.9% and 27.3% per annum respectively. EPS is expected to grow by 33.9% per annum. Return on equity is forecast to be 14% in 3 years.
Key information
33.9%
Earnings growth rate
33.9%
EPS growth rate
Pharmaceuticals earnings growth | 18.0% |
Revenue growth rate | 27.3% |
Future return on equity | 14.0% |
Analyst coverage | Low |
Last updated | 09 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,000 | 200 | 120 | 229 | 1 |
12/31/2025 | 784 | 147 | 57 | 147 | 2 |
12/31/2024 | 597 | 109 | -29 | 101 | 1 |
3/31/2024 | 458 | 73 | -221 | 80 | N/A |
12/31/2023 | 435 | 70 | -193 | 85 | N/A |
9/30/2023 | 427 | 60 | -188 | 89 | N/A |
6/30/2023 | 402 | 66 | -118 | 82 | N/A |
3/31/2023 | 396 | 64 | -85 | 83 | N/A |
12/31/2022 | 396 | 64 | -40 | 96 | N/A |
9/30/2022 | 368 | 57 | -6 | 61 | N/A |
6/30/2022 | 360 | 56 | 2 | 72 | N/A |
3/31/2022 | 374 | 64 | -2 | 57 | N/A |
12/31/2021 | 387 | 61 | -12 | 52 | N/A |
9/30/2021 | 387 | 61 | -18 | 48 | N/A |
6/30/2021 | 397 | 53 | -8 | 44 | N/A |
3/31/2021 | 401 | 62 | 15 | 78 | N/A |
12/31/2020 | 379 | 60 | 29 | 81 | N/A |
12/31/2019 | 327 | 48 | 0 | 31 | N/A |
12/31/2018 | 278 | 30 | 35 | 66 | N/A |
12/31/2017 | 194 | 34 | N/A | 58 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688117's forecast earnings growth (33.9% per year) is above the savings rate (2.9%).
Earnings vs Market: 688117's earnings (33.9% per year) are forecast to grow faster than the CN market (22.1% per year).
High Growth Earnings: 688117's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688117's revenue (27.3% per year) is forecast to grow faster than the CN market (13.6% per year).
High Growth Revenue: 688117's revenue (27.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688117's Return on Equity is forecast to be low in 3 years time (14%).